{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T05:39:59Z","timestamp":1769578799173,"version":"3.49.0"},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"vor","delay-in-days":84,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.neuropharm.2022.109375","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T20:28:30Z","timestamp":1671136110000},"page":"109375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines"],"prefix":"10.1016","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6128-9632","authenticated-orcid":false,"given":"D.J.","family":"Heal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gosden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.K.","family":"Atterwill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2022.109375_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1600-0773.1989.tb00623.x","article-title":"Characterization of the discriminative stimulus properties induced by 5-HT1 and 5-HT2 agonists in rats","volume":"64","author":"Arnt","year":"1989","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib2","first-page":"77S","article-title":"Agonist-directed signaling of serotonin 5-HT2C receptors: differences between serotonin and lysergic acid diethylamide (LSD)","volume":"21","author":"Backstrom","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109375_bib3","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.ajpath.2015.12.014","article-title":"Ketamine-induced apoptosis in normal human urothelial cells","volume":"186","author":"Baker","year":"2016","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109375_bib4","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0091-3057(96)00334-6","article-title":"Assessment of the MDA and MDMA optical isomers in a stimulant-hallucinogen discrimination","volume":"57","author":"Baker","year":"1997","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109375_bib5","series-title":"The Serotonin Receptors: Comparing the Binding Affinity of 5 Psychedelics","author":"Bauer","year":"2019"},{"key":"10.1016\/j.neuropharm.2022.109375_bib6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0074-7742(09)88010-0","article-title":"Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA)","volume":"88","author":"Baumann","year":"2009","journal-title":"Int review Neurobiol"},{"key":"10.1016\/j.neuropharm.2022.109375_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0376-8716(86)90047-5","article-title":"Self-administration of methylenedioxymethamphetamine (MDMA) by rhesus monkeys","volume":"18","author":"Beardsley","year":"1986","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2022.109375_bib8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/npp.2012.178","article-title":"Brain serotonin function in MDMA (ecstasy) users: evidence for persisting neurotoxicity","volume":"38","author":"Benningfield","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109375_bib9","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s00213-004-2108-z","article-title":"Complex discriminative stimulus properties of (+)lysergic acid diethylamide (LSD) in C57Bl\/6J mice","volume":"179","author":"Benneyworth","year":"2005","journal-title":"Psychopharmacol."},{"issue":"24","key":"10.1016\/j.neuropharm.2022.109375_bib10","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm000339w","article-title":"Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines","volume":"43","author":"Blair","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2022.109375_bib11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/BF00841009","article-title":"Study by the intracerebral microdialysis method of the effects of atypical neuroleptics and anxiolytics on striatal release and metabolism of dopamine in awake rats","volume":"111","author":"Bogdanov","year":"1991","journal-title":"Biull Eksp Biol Med"},{"key":"10.1016\/j.neuropharm.2022.109375_bib12","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1046\/j.1471-4159.1994.63031163.x","article-title":"Fenfluramine releases serotonin from human brain nerve endings by a dual mechanism","volume":"63","author":"Bonanno","year":"1994","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2022.109375_bib13","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1007\/s00213-020-05648-z","article-title":"The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats","volume":"237","author":"Brandt","year":"2020","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib14","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/ph13110334","article-title":"Toxicokinetics and toxicodynamics of ayahuasca alkaloids N,N-Dimethyltryptamine (DMT), harmine, harmaline and tetrahydroharmine: clinical and forensic impact","volume":"13","author":"Brito-da-Costa","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.neuropharm.2022.109375_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neuropharm.2017.11.028","article-title":"A regulatory perspective on the evaluation of hallucinogen drugs for human use","volume":"142","author":"Calderon","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109375_bib16","series-title":"Considerations in Assessing the Abuse Potential of Psychedelics during Drug Development","author":"Calderon","year":"2022"},{"key":"10.1016\/j.neuropharm.2022.109375_bib17","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0306-4522(89)90285-6","article-title":"Serotonin release estimated by transcortical dialysis in freely-moving rats","volume":"32","author":"Carboni","year":"1989","journal-title":"Neurosciences"},{"key":"10.1016\/j.neuropharm.2022.109375_bib18","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0022-3565(25)22199-1","article-title":"Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline","volume":"246","author":"Callahan","year":"1988","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109375_bib19","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2022.109375_bib20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib21","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109375_bib22","series-title":"Assessment of Abuse Potential of Drugs. Guidance for Industry","year":"2017"},{"key":"10.1016\/j.neuropharm.2022.109375_bib23","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/S0028-3908(00)00032-0","article-title":"Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine","volume":"39","author":"Cheetham","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109375_bib24","series-title":"Guidance of the Non-clinical Investigation of the Dependence Potential of Medicinal Products","year":"2006"},{"key":"10.1016\/j.neuropharm.2022.109375_bib25","first-page":"299","article-title":"Involvement of 5-hydroxytryptamine-2A (5-HT2A) receptors in the mediation of the discriminative stimulus properties of \u00b1DOI in rats","volume":"49","author":"Chojnacka-W\u00f3jcik","year":"1997","journal-title":"Pol. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib26","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0022-3565(25)33038-7","article-title":"A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist","volume":"221","author":"Colpaert","year":"1982","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109375_bib27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF00401509","article-title":"A possible correlation between drug-induced hallucinations in man and a behavioural response in mice","volume":"11","author":"Corne","year":"1967","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2022.109375_bib28","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neuropharm.2015.01.003","article-title":"Intravenous self-administration of mephedrone, methylone and MDMA in female rats","volume":"92","author":"Creehan","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109375_bib29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF00690929","article-title":"Neuropharmacological reassessment of the discriminative stimulus properties of d-lysergic acid diethylamide (LSD)","volume":"91","author":"Cunningham","year":"1987","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.drugalcdep.2013.12.019","article-title":"Therapeutic infusions of ketamine: do the psychoactive effects matter?","volume":"136","author":"Dakwar","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2022.109375_bib31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0091-3057(97)00548-0","article-title":"Cocaine and selective monoamine uptake blockers (sertraline, nisoxetine, and GBR 12935) prevent the d-fenfluramine-induced head-twitch response in mice","volume":"60","author":"Darmani","year":"1998","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109375_bib32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.drugalcdep.2017.07.041","article-title":"Discriminative stimulus and locomotor effects of para-substituted and benzofuran analogs of amphetamine","volume":"180","author":"Dolan","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2022.109375_bib33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","article-title":"Ketamine Assisted Psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy","volume":"51","author":"Dore","year":"2019","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.neuropharm.2022.109375_bib34","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.amjcard.2007.06.045","article-title":"Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease","volume":"100","author":"Droogmans","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib35","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0192623310378027","article-title":"Drug-induced valvulopathy: an update","volume":"38","author":"Elangbam","year":"2010","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib36","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00213-013-3303-6","article-title":"Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function","volume":"231","author":"Eshleman","year":"2014","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib37","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00213-005-0005-8","article-title":"Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse","volume":"181","author":"Fantegrossi","year":"2005","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib38","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00213-002-1021-6","article-title":"3,4-Methylenedioxymethamphetamine (MDMA, \"ecstasy\") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement","volume":"161","author":"Fantegrossi","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109375_bib39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00008877-200403000-00007","article-title":"Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys","volume":"15","author":"Fantegrossi","year":"2004","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib40","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0028-3908(97)00121-4","article-title":"Further investigations of the interactions of antipsychotics with the (-)2,5-dimethoxy-4-methylamphetamine (DOM) discriminative stimulus","volume":"36","author":"Fiorella","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109375_bib41","first-page":"326","article-title":"Antagonism of apomorphine-induced cage climbing behaviour and methamphetamine stereotypy by fenfluramine in mice","volume":"28","author":"Gada","year":"1984","journal-title":"Indian J. Physiol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib42","series-title":"Determination of the Concentrations of D-Amphetamine, Neurotransmitters and Various Metabolites in Microdialysates Taken from the Brains of Freely-Moving Rats","author":"Gill","year":"2016"},{"key":"10.1016\/j.neuropharm.2022.109375_bib43","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/0091-3057(85)90096-6","article-title":"Mechanistic studies on DOM as a discriminative stimulus","volume":"23","author":"Glennon","year":"1985","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109375_bib44","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0014-2999(83)90196-6","article-title":"DOM-stimulus generalization to LSD and other hallucinogenic indolealkylamines","volume":"86","author":"Glennon","year":"1983","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib45","first-page":"807","article-title":"Discriminative stimulus properties of MDA analogs","volume":"17","author":"Glennon","year":"1982","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109375_bib46","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0306-3623(84)90016-8","article-title":"1-(2,3-Methylenedioxyphenyl)-2-aminopropane (2,3-MDA): a preliminary investigation","volume":"15","author":"Glennon","year":"1984","journal-title":"Gen. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib47","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0091-3057(88)90001-9","article-title":"Stimulus properties of methylenedioxyphenyl)-2-aminopropane (MDA) analogs","volume":"29","author":"Glennon","year":"1988","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109375_bib48","series-title":"Proceedings of the College on Problems of Drug Dependence 79th Annual Meeting","article-title":"A comparison of the physical dependence syndromes produced in rats by morphine and diazepam","author":"Goddard","year":"2017"},{"key":"10.1016\/j.neuropharm.2022.109375_bib49","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.vascn.2016.07.004","article-title":"An intravenous self-administration procedure for assessing the reinforcing effects of hallucinogens in nonhuman primates","volume":"82","author":"Goodwin","year":"2016","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.neuropharm.2022.109375_bib50","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0091-3057(03)00029-7","article-title":"Serotonergic-dopaminergic mediation of MDMA's discriminative stimulus effects in a three-choice discrimination","volume":"74","author":"Goodwin","year":"2003","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109375_bib51","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/0269881106063264","article-title":"Studies on striatal neurotoxicity caused by the 3,4-methylenedioxymethamphetamine\/malonate combination: implications for serotonin\/dopamine interactions","volume":"20","author":"Go\u00f1i-Allo","year":"2006","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib52","doi-asserted-by":"crossref","first-page":"305","DOI":"10.31887\/DCNS.2009.11.3\/egmayfrank","article-title":"Neurotoxicity of drugs of abuse--the case of methylenedioxyamphetamines (MDMA, ecstasy), and amphetamines","volume":"11","author":"Gouzoulis-Mayfrank","year":"2009","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109375_bib53","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1124\/jpet.121.000988","article-title":"Preclinical assessment of the abuse potential of purified botanical cannabidiol: self-administration, drug discrimination, and physical dependence","volume":"382","author":"Gray","year":"2022","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109375_bib54","series-title":"Neuropharmacology of Serotonin","first-page":"326","article-title":"The effects of drugs on serotonin-mediated behavioural models","author":"Green","year":"1985"},{"key":"10.1016\/j.neuropharm.2022.109375_bib55","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1124\/jpet.106.112946","article-title":"5-Hydroxytryptamine (serotonin)2A receptors in rat anterior cingulate cortex mediate the discriminative stimulus properties of d-lysergic acid diethylamide","volume":"320","author":"Gresch","year":"2007","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109375_bib56","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/sj.npp.1300711","article-title":"Behavioral tolerance to lysergic acid diethylamide is associated with reduced serotonin-2A receptor signaling in rat cortex","volume":"30","author":"Gresch","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109375_bib57","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cpt1975185part1563","article-title":"A comparison of fenfluramine and amphetamine in man","volume":"18","author":"Griffith","year":"1975","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2022.109375_bib58","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib59","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109375_bib60","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1471-4159.1996.66010243.x","article-title":"Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions","volume":"66","author":"Gudelsky","year":"1996","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2022.109375_bib61","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0014-2999(94)90669-6","article-title":"Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists","volume":"264","author":"Gudelsky","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107933","article-title":"Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species","volume":"167","author":"Halberstadt","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109375_bib63","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.lfs.2013.07.014","article-title":"Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine","volume":"97","author":"Halpin","year":"2014","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2022.109375_bib64","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.bjp.0702067","article-title":"A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents","volume":"125","author":"Heal","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib65","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.neuropharm.2009.08.020","article-title":"The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety","volume":"57","author":"Heal","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109375_bib66","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neuropharm.2014.06.012","article-title":"Dopamine reuptake transporter (DAT) \"inverse agonism\" - a novel hypothesis to explain the enigmatic pharmacology of cocaine","volume":"87","author":"Heal","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109375_bib67","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neuropharm.2018.01.049","article-title":"Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans","volume":"142","author":"Heal","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109375_bib68","author":"Heal"},{"key":"10.1016\/j.neuropharm.2022.109375_bib69","series-title":"Central Serotonin Receptors and Psychotropic Drugs","first-page":"56","article-title":"Pharmacological identification of 5-HT receptor subtypes using behavioural models","author":"Heal","year":"1992"},{"key":"10.1016\/j.neuropharm.2022.109375_bib70","series-title":"Proceedings of the American College of Neuropsychopharmacology Annual Meeting","article-title":"Relative contributions of drug re-exposure and salient cues in the reinstatement of cocaine and heroin seeking; implications for the treatment of substance use disorders","author":"Heal","year":"2019"},{"key":"10.1016\/j.neuropharm.2022.109375_bib71","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/0269881113482532","article-title":"Amphetamine, past and present-a pharmacological and clinical perspective","volume":"27","author":"Heal","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib72","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0278-5846(98)00031-1","article-title":"A comparison of N,N-dimethyltryptamine, harmaline, and selected congeners in rats trained with LSD as a discriminative stimulus","volume":"22","author":"Helsley","year":"1998","journal-title":"Prog Neuropsychopharmacol Biol Psychiat"},{"key":"10.1016\/j.neuropharm.2022.109375_bib73","series-title":"Psychedelic Drug Abuse Potential Assessment Research for New Drug Applications and Controlled Substances Act Scheduling","author":"Henningfield","year":"2022"},{"key":"10.1016\/j.neuropharm.2022.109375_bib74","article-title":"Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: a United States perspective","author":"Henningfield","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib75","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/toxsci\/kft275","article-title":"Glial cell response to 3,4-(\u00b1)-methylenedioxymethamphetamine and its metabolites","volume":"138","author":"Herndon","year":"2014","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109375_bib76","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fcvm.2017.00048","article-title":"The effects of serotonin in immune cells","volume":"4","author":"Herr","year":"2017","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.neuropharm.2022.109375_bib77","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3810\/pgm.2013.11.2713","article-title":"The safety and efficacy of lorcaserin in the management of obesity","volume":"125","author":"Hess","year":"2013","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.neuropharm.2022.109375_bib78","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41386-019-0569-3","article-title":"Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects","volume":"45","author":"Holze","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109375_bib79","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pharmthera.2011.03.008","article-title":"Serotonin receptors and heart valve disease - it was meant 2B","volume":"132","author":"Hutcheson","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2022.109375_bib80","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/npp.2011.338","article-title":"Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study","volume":"37","author":"Ibrahim","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109375_bib81","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1021\/jm00069a010","article-title":"Antagonism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5-HT2- versus 5-HT1C-selective antagonist","volume":"36","author":"Ismaiel","year":"1993","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2022.109375_bib82","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109375_bib83","first-page":"249","article-title":"Fenfluramine-induced head-twitch response in mice and its modification by certain drugs influencing the central 5-hydroxytryptamine function","volume":"27","author":"Joshi","year":"1983","journal-title":"Indian J. Physiol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib84","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S0091-3057(97)00527-3","article-title":"The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens","volume":"59","author":"Kankaanp\u00e4\u00e4","year":"1998","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109375_bib85","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.pbb.2004.05.021","article-title":"Stimulus effects of three sulfur-containing psychoactive agents","volume":"78","author":"Khorana","year":"2004","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109375_bib86","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF02976533","article-title":"NMDA receptor antagonists enhance 5-HT2 receptor-mediated behavior, head-twitch response, in PCPA-treated mice","volume":"22","author":"Kim","year":"1999","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.neuropharm.2022.109375_bib87","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/S0024-3205(98)00519-0","article-title":"NMDA receptor antagonists enhance 5-HT2 receptor-mediated behavior, head-twitch response, in mice","volume":"63","author":"Kim","year":"1998","journal-title":"Life Sci."},{"issue":"5857","key":"10.1016\/j.neuropharm.2022.109375_bib88","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/bmj.2.5857.49-b","article-title":"Abuse of fenfluramine","volume":"2","author":"Levin","year":"1973","journal-title":"Br. Med. J."},{"key":"10.1016\/j.neuropharm.2022.109375_bib89","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.lfs.2005.08.027","article-title":"Comparison of psychic emergence reactions after (+\/-)-ketamine and (+)-ketamine in mice","volume":"78","author":"Liu","year":"2006","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2022.109375_bib90","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1177\/0269881111420188","article-title":"Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness","volume":"25","author":"MacLean","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib91","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1021\/acschemneuro.0c00129","article-title":"Investigation of the 2,5-dimethoxy motif in phenethylamine serotonin 2A receptor agonists","volume":"11","author":"Marcher-R\u00f8rsted","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109375_bib92","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00213-008-1238-0","article-title":"Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen","volume":"203","author":"Marona-Lewicka","year":"2009","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib93","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/BF02245809","article-title":"Complex stimulus properties of LSD: a drug discrimination study with alpha 2-adrenoceptor agonists and antagonists","volume":"120","author":"Marona-Lewicka","year":"1995","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib94","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s002130050646","article-title":"Drug discrimination studies of the interoceptive cues produced by selective serotonin uptake inhibitors and selective serotonin releasing agents","volume":"138","author":"Marona-Lewicka","year":"1998","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib95","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jad.2019.12.023","article-title":"The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: a systematic review","volume":"264","author":"Mathai","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2022.109375_bib96","first-page":"53","article-title":"Strategies for detecting subclinical monoamine depletions in humans","volume":"136","author":"McCann","year":"1993","journal-title":"NIDA Res. Monogr."},{"key":"10.1016\/j.neuropharm.2022.109375_bib97","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000026665","article-title":"(+\/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies","volume":"42","author":"McCann","year":"2000","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.neuropharm.2022.109375_bib98","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0022-3565(25)38720-3","article-title":"Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated","volume":"269","author":"McCann","year":"1994","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109375_bib99","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/00002018-199615020-00003","article-title":"Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy')","volume":"15","author":"McCann","year":"1996","journal-title":"Drug Saf."},{"issue":"9","key":"10.1016\/j.neuropharm.2022.109375_bib100","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/sj.npp.1300736","article-title":"Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology","volume":"30","author":"McCann","year":"2005","journal-title":"Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib101","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3389\/fphar.2019.01406","article-title":"Neurochemical and behavioral profiling in male and female rats of the psychedelic agent 25I-NBOMe","volume":"10","author":"Miliano","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.695335","article-title":"This is something that changed my life\": a qualitative study of patients' experiences in a clinical trial of ketamine treatment for alcohol use disorders","volume":"12","author":"Mollaahmetoglu","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109375_bib103","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/7854_2016_29","article-title":"The discriminative stimulus properties of hallucinogenic and dissociative anesthetic drugs","volume":"39","author":"Mori","year":"2018","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.neuropharm.2022.109375_bib104","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1017\/S1461145712000582","article-title":"Single Oral Doses of 3,4-methylenedioxymetamphetamine (MDMA, Ecstasy) produce long lasting serotonergic deficits in non-human primates: relationship to plasma drug and metabolite concentrations","volume":"16","author":"Mueller","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib105","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neubiorev.2018.11.004","article-title":"Neuroimaging of chronic MDMA (\"ecstasy\") effects: a meta-analysis","volume":"96","author":"M\u00fcller","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2022.109375_bib106","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109375_bib107","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0014-2999(91)90664-C","article-title":"Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues","volume":"200","author":"Nash","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib108","author":"NeuroDeRisk Database"},{"key":"10.1016\/j.neuropharm.2022.109375_bib109","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1046\/j.1471-4159.1996.67062521.x","article-title":"Characterisation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH-SY5Y: comparative stimulation by hallucinogenic drugs","volume":"67","author":"Newton","year":"1996","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2022.109375_bib110","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1021\/jm00051a011","article-title":"1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A\/2C agonist","volume":"37","author":"Nichols","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2022.109375_bib111","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1021\/jm020153s","article-title":"Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD)","volume":"45","author":"Nichols","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2022.109375_bib112","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1021\/jm00160a035","article-title":"Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class","volume":"29","author":"Nichols","year":"1986","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2022.109375_bib113","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1021\/jm00372a015","article-title":"Substituent branching in phenethylamine-type hallucinogens: a comparison of 1-[2,5-dimethoxy-4-(2-butyl)phenyl]-2-aminopropane and 1-[2,5-dimethoxy-4-(2-methylpropyl)phenyl]-2-aminopropane","volume":"27","author":"Oberlender","year":"1984","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2022.109375_bib114","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0022-3565(25)22433-8","article-title":"Neurotoxicity profiles of substituted amphetamines in the C57BL\/61 mouse","volume":"270","author":"O'Callaghan","year":"1994","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109375_bib116","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1523\/JNEUROSCI.08-08-02788.1988","article-title":"Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity","volume":"8","author":"O'Hearn","year":"1988","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109375_bib117","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/YCT.0b013e3181c3b0aa","article-title":"Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia","volume":"26","author":"Okamoto","year":"2010","journal-title":"J. ECT"},{"key":"10.1016\/j.neuropharm.2022.109375_bib118","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial","volume":"49","author":"Palhano-Fontes","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2022.109375_bib119","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","article-title":"The pharmacology of lysergic acid diethylamide: a review","volume":"14","author":"Passie","year":"2008","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neuropharm.2022.109375_bib120","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/FBP.0b013e328349fc1b","article-title":"Salvinorin B derivatives, EOM-Sal B and MOM-Sal B, produce stimulus generalization in male Sprague-Dawley rats trained to discriminate salvinorin A","volume":"22","author":"Peet","year":"2011","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib121","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/sj.npp.1301491","article-title":"Dissociation of the neurochemical and behavioral toxicology of MDMA ('Ecstasy') by citalopram","volume":"33","author":"Piper","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109375_bib122","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.bjp.0702751","article-title":"Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells","volume":"128","author":"Porter","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib123","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000438675","article-title":"Ketamine-induced hallucinations","volume":"48","author":"Powers","year":"2015","journal-title":"Psychopathology"},{"key":"10.1016\/j.neuropharm.2022.109375_bib124","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.35082","article-title":"Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor","volume":"7","author":"Preller","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.neuropharm.2022.109375_bib125","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cub.2016.12.030","article-title":"The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation","volume":"27","author":"Preller","year":"2017","journal-title":"Curr. Biol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib126","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1073\/pnas.1815129116","article-title":"Effective connectivity changes in LSD-induced altered states of consciousness in humans","volume":"116","author":"Preller","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2022.109375_bib127","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.biopsych.2009.04.029","article-title":"Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression","volume":"66","author":"Price","year":"2009","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109375_bib128","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/BF01694534","article-title":"Mast cells in neuroimmune function: neuroimmune and neuropharmacological perspectives","volume":"20","author":"Purcell","year":"1995","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2022.109375_bib129","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1007\/s00213-015-4041-8","article-title":"Preclinical characterization of toluene as a non-classical hallucinogen drug in rats: participation of 5-HT, dopamine and glutamate systems","volume":"232","author":"Rivera-Garc\u00eda","year":"2015","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib130","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1002\/hbm.23224","article-title":"LSD alters eyes-closed functional connectivity within the early visual cortex in a retinotopic fashion","volume":"37","author":"Roseman","year":"2016","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.neuropharm.2022.109375_bib131","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib132","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/0269881120970879","article-title":"Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: results from a randomized, controlled trial","volume":"35","author":"Rothberg","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib133","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0163-7258(02)00234-6","article-title":"Therapeutic and adverse actions of serotonin transporter substrates","volume":"95","author":"Rothman","year":"2002","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2022.109375_bib134","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3","article-title":"Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin","volume":"39","author":"Rothman","year":"2001","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2022.109375_bib135","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.neuropharm.2022.109375_bib136","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/0269881113513850","article-title":"Differences in the neurochemical and behavioural profiles of lisdexamfetamine methylphenidate and modafinil revealed by simultaneous dual-probe microdialysis and locomotor activity measurements in freely-moving rats","volume":"28","author":"Rowley","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib137","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.neuropharm.2012.07.008","article-title":"Lisdexamfetamine and immediate release d amfetamine \u2013 differences in pharmacokinetic\/pharmacodynamic relationships revealed by striatal microdialysis in freely moving rats with simultaneous determination of plasma drug concentrations and locomotor activity","volume":"63","author":"Rowley","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109375_bib138","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1007\/s00213-019-05279-z","article-title":"Replication and extension of a model predicting response to psilocybin","volume":"236","author":"Russ","year":"2019","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib139","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00213-019-05241-z","article-title":"Effects of dopaminergic and serotonergic compounds in rats trained to discriminate a high and a low training dose of the synthetic cathinone mephedrone","volume":"236","author":"Saber","year":"2019","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib140","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1248\/bpb.b14-00315","article-title":"Effect of psilocin on extracellular dopamine and serotonin levels in the mesoaccumbens and mesocortical pathway in awake rats","volume":"38","author":"Sakashita","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.neuropharm.2022.109375_bib141","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/BF02244428","article-title":"Choroid plexus epithelial cells in primary culture: a model of 5HT1C receptor activation by hallucinogenic drugs","volume":"105","author":"Sanders-Bush","year":"1991","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib142","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0022-3565(25)22189-9","article-title":"Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis","volume":"246","author":"Sanders-Bush","year":"1988","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109375_bib143","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0014-2999(94)90643-2","article-title":"Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone","volume":"264","author":"Schreiber","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib144","doi-asserted-by":"crossref","first-page":"6242","DOI":"10.1016\/j.bmc.2008.04.030","article-title":"Hybrid' benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines","volume":"16","author":"Schultz","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.neuropharm.2022.109375_bib145","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/cpt.776","article-title":"Psychedelic drugs as therapeutics: no illusions about the challenges","volume":"103","author":"Sellers","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2022.109375_bib146","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1124\/mol.104.009266","article-title":"Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor","volume":"68","author":"Setola","year":"2005","journal-title":"Mol. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109375_bib147","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1124\/mol.63.6.1223","article-title":"3,4-methylenedioxymethamphetamine (MDMA, \"Ecstasy\") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro","volume":"63","author":"Setola","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib148","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00213-002-1252-6","article-title":"Discriminative stimulus properties of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(+\/-)DOI] in C57BL\/6J mice","volume":"166","author":"Smith","year":"2003","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib149","series-title":"Proceedings of the College on Problems of Drug Dependence 1st Virtual Annual Meeting","article-title":"Differences in the relative contribution of drug re-exposure and salient cues in the reinstatement of cocaine, heroin and nicotine seeking","author":"Smith","year":"2020"},{"key":"10.1016\/j.neuropharm.2022.109375_bib150","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/0269881118822111","article-title":"Investigation of the reinforcing potential of samidorphan and naltrexone by fixed and progressive ratio intravenous self-administration testing in heroin-maintained rats","volume":"33","author":"Smith","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib151","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2174\/138920110791591436","article-title":"Mechanisms of MDMA (ecstasy)-induced oxidative stress, mitochondrial dysfunction, and organ damage","volume":"11","author":"Song","year":"2010","journal-title":"Curr. Pharmaceut. Biotechnol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib152","first-page":"287","article-title":"Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression","volume":"34","author":"Sos","year":"2013","journal-title":"Neuroendocrinol. Lett."},{"key":"10.1016\/j.neuropharm.2022.109375_bib153","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1124\/jpet.111.185728","article-title":"Effects of repeated 3,4-methylenedioxymethamphetamine administration on neurotransmitter efflux and sensory-evoked discharge in the ventral posterior medial thalamus","volume":"340","author":"Starr","year":"2012","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109375_bib154","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/0269881121998321","article-title":"A qualitative and quantitative account of patient's experiences of ketamine and its antidepressant properties","volume":"35","author":"Sumner","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109261","article-title":"Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats","volume":"231","author":"Synan","year":"2022","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2022.109375_bib156","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1124\/jpet.107.133348","article-title":"Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization","volume":"325","author":"Thomsen","year":"2008","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109375_bib157","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0026-895X(25)11222-4","article-title":"Binding characteristics of a radiolabeled agonist and antagonist at central nervous system alpha noradrenergic receptors","volume":"13","author":"U'Prichard","year":"1977","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib158","first-page":"1","article-title":"Therapeutic effect of an ayahuasca analogue in clinically depressed patients: a longitudinal observational study","volume":"24","author":"van Oorsouw","year":"2022","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib159","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.neuropharm.2015.08.030","article-title":"Intravenous self-administration of entactogen-class stimulants in male rats","volume":"99","author":"Vandewater","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109375_bib160","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-016-4396-5","article-title":"The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies","volume":"233","author":"Vegting","year":"2016","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib161","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/BF00430748","article-title":"Training dose as a factor in LSD-saline discrimination","volume":"76","author":"White","year":"1982","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib162","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1007\/s00213-003-1636-2","article-title":"Serotonergic\/glutamatergic interactions: the effects of mGlu2\/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli","volume":"172","author":"Winter","year":"2004","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109375_bib163","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/0028-3908(87)90168-7","article-title":"Phencyclidine-induced head-weaving and head-twitch through interaction with 5-HT1 and 5-HT2 receptors in reserpinized rats","volume":"26","author":"Yamaguchi","year":"1987","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109375_bib164","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/YCT.0b013e3182a4b4c6","article-title":"Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: a randomized, double-blind study","volume":"30","author":"Yoosefi","year":"2014","journal-title":"J. ECT"},{"key":"10.1016\/j.neuropharm.2022.109375_bib165","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/0024-3205(82)90446-5","article-title":"Comparative discriminative stimulus effects of 5-methoxy-N,N-dimethyltryptamine and LSD","volume":"30","author":"Young","year":"1982","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2022.109375_bib166","doi-asserted-by":"crossref","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109375_bib167","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3389\/fphar.2019.01325","article-title":"The impact of ayahuasca on suicidality: results from a randomized controlled trial","volume":"10","author":"Zeifman","year":"2019","journal-title":"Front. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822004348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822004348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:21:50Z","timestamp":1758439310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822004348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":166,"alternative-id":["S0028390822004348"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109375","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109375","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109375"}}